ArticleMedical oncology (Northwood, London, England)2025
Synthesis, characterization, and evaluation of the cytotoxic effects of caffeine nanoparticles on K562 cancer cell line.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Red single wavelength emitting up-conversion nanoparticles modulate cellular dynamics and gene expression in T24 bladder cancer cells.Scientific reports · 2025Article
- Nano-phytochemical-based formulations as promising opportunities for prostate cancer therapy and management: a comprehensive narrative review.Medical oncology (Northwood, London, England) · 2025Review
- Enhanced pro-apoptotic and pro-oxidative effects of hesperidin on LNCaP prostate cancer cell line through nano-emulsification.Molecular biology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Caffeine (1, 3, 7-trimethylxanthine) can be used as an anti-cancer compound in low concentrations. Considering this potential and the advantages of nanotechnology, including targeted delivery and low doses of compounds, caffeine nanoparticles were produced using a spontaneous nanoemulsion production method. Nanoparticles with an average diameter of 168 ± 1.03 nm, a polydispersity index of 0.2, and desirable stability were produced. After treatment with free caffeine and caffeine nanoemulsion, the viability of K562 cancer cells was measured using the MTT test, which showed that free caffeine and caffeine nanoemulsion, after 48 h, killed 50% of cancer cells at a concentration of 555.23 ± 1.7 µg/ml and 285.71 ± 3 µg/ml, respectively. Evaluation of genes involved in the induction of apoptosis in cancer cells showed the prominent role of caspase-3 in the induction of apoptosis. Also, free caffeine and caffeine nanoemulsion increased the expression level of P53 by 2- and 4-fold compared to the control group, and the expression ratio of Bax/Bcl2 increased by 10- and 15-fold, respectively. The biocompatibility evaluation test results showed that the caffeine nanoemulsion in the concentrations used in this study had no cytotoxic effects on PMBC and RBC cells and could be used for therapeutic purposes. In general, the results of this study showed that caffeine nanoemulsions not only have more potent anti-cancer activity than free caffeine but also show minimal cytotoxicity and better biocompatibility than free caffeine on normal cells. Our findings show that caffeine nanoparticles are a potential candidate for cancer treatment use as a therapeutic agent.
Indexed as
Identifiers
40450083What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.